AstraZeneca’s Calquence wins FDA nod for CLL treatment

AstraZeneca announced in Wilmington, Del. that the U.S. Food and Drug Administration has approved its cancer drug Calquence in combination with venetoclax for treating adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, expanding the pharmaceutical company's oncology treatment options. The approval comes as AstraZeneca shares trade near their 52-week high of $212.71, with the stock delivering a 44% return over the past year. The pharmaceutical giant's market capitalization stands at $320 billion, reflecting investor confidence in its oncology pipeline. This FDA nod for Calquence represents a significant milestone in the treatment of these blood cancers, potentially offering new hope to patients diagnosed with CLL and small lymphocytic lymphoma. The approval strengthens AstraZeneca's position in the competitive oncology market and adds to its portfolio of cancer treatments, with the company having invested heavily in research and development of oncology drugs.